Ambenonium

Summary

Ambenonium (CHEMBL1652) is an approved small-molecule EC 3.1.1.8 (cholinesterase) inhibitor (ATC N07AA30).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N07AA30
• Chemistry: 537.6 Da · C28H42Cl2N4O2+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1652
Name	Ambenonium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2131
ChEBI	CHEBI:2627
ATC	N07AA30
Molecular formula	C28H42Cl2N4O2+2
Molecular weight	537.6
InChIKey	OMHBPUNFVFNHJK-UHFFFAOYSA-P

SMILES: CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl

IUPAC name: (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium

ChEBI definition: A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.

Pharmacological roles (ChEBI): EC 3.1.1.8 (cholinesterase) inhibitor.

Also known as: Ambenonium, Ambenonium cation, Ambenonium ion, SID11113478, SID26756578, ambenonium, AMBENONIUM

Parent form; salt/anhydrous children: CHEMBL1200541

Patent coverage: 495 distinct patent families (1,732 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Inositol monophosphatase 1, Alpha-2C adrenergic receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Mu-type opioid receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 17 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P23795	9.92	IC50	0.12	nM	CHEMBL_ACT_2575665
OPRK1	6.16	AC50	700	nM	CHEMBL_ACT_25130053
CHRM3	5.96	AC50	1100	nM	CHEMBL_ACT_25137351
CHRM1	5.8	AC50	1600	nM	CHEMBL_ACT_25136153
CHRM2	5.66	AC50	2200	nM	CHEMBL_ACT_25214398
ADRA2C	5.6	AC50	2500	nM	CHEMBL_ACT_25148571
OPRM1	5.37	AC50	4300	nM	CHEMBL_ACT_25147325
SLC6A4	5.21	AC50	6100	nM	CHEMBL_ACT_25150997
KCNH2	5.11	AC50	7800	nM	CHEMBL_ACT_25118850
SLC6A2	5	AC50	10000	nM	CHEMBL_ACT_25145672

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).